Pfizer announced the appointment of James List as the head of its Internal Medicine portfolio, which includes the development of cardiovascular and obesity medicines. This strategic leadership appointment reinforces the company's commitment to the obesity drug market.
The move follows CEO Albert Bourla's earlier declaration that Pfizer is 'all in' on obesity drug development. Mr. List's role will be crucial in advancing Pfizer's pipeline candidates in this highly competitive and lucrative therapeutic area.
This appointment signals a dedicated focus on building a strong presence in the obesity market, leveraging internal programs and external opportunities to deliver new weight-loss therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.